A 56-year-old man presents to the clinic for a follow-up evaluation of gout. He has a hist… — USMLE Step 3

A 56-year-old man presents to the clinic for a follow-up evaluation of gout. He has a history of three acute gouty flares in the past year, affecting his left first metatarsophalangeal joint and right knee. Five weeks ago, he was started on allopurinol $100\text{ mg}$ daily for urate-lowering therapy and colchicine $0.6\text{ mg}$ daily for flare prophylaxis. His medical history is significant for hypertension and stage 3a chronic kidney disease. His estimated glomerular filtration rate is $52\text{ mL/min/1.73 m}^2$ . Today, he reports feeling well and has not experienced any joint pain since starting the medications.

Laboratory results from today are as follows:

Laboratory Parameter	Result	Reference Range
Serum uric acid	$7.8\text{ mg/dL}$	$3.5 - 7.2\text{ mg/dL}$
Serum creatinine	$1.4\text{ mg/dL}$	$0.6 - 1.2\text{ mg/dL}$
Alanine aminotransferase (ALT)	$22\text{ U/L}$	$10 - 40\text{ U/L}$

Which of the following is the most appropriate next step in the management of this patient?

Increase the allopurinol dose to $200\text{ mg}$ daily and repeat the serum uric acid level in $4$ weeksAnswer
B
Continue the current medication regimen and repeat the serum uric acid level in $6$ months
C
Discontinue the colchicine because the patient has been flare-free for over a month
D
Switch allopurinol to probenecid to increase renal urate excretion
E
Order a $24$ -hour urine uric acid collection to evaluate for urate overproduction

Answer

Increase the allopurinol dose to 200 mg daily and repeat the serum uric acid level in 4 weeks.

The patient has symptomatic gout and was appropriately started on allopurinol and colchicine. The primary goal of urate-lowering therapy (ULT) is to maintain a serum uric acid level of

< 6.0\text{ mg/dL}

(and

< 5.0\text{ mg/dL}

in patients with tophaceous gout) to promote the dissolution of monosodium urate crystals. His current level is

7.8\text{ mg/dL}

, indicating that the

100\text{ mg}

dose is subtherapeutic. In patients with chronic kidney disease, allopurinol is typically initiated at a low dose (e.g.,

50-100\text{ mg}

daily) to minimize the risk of allopurinol hypersensitivity syndrome. However, a common clinical misconception is that the dose must be strictly capped based on renal function. Current guidelines emphasize that allopurinol can and should be gradually up-titrated every 2 to 5 weeks until the uric acid target is achieved, regardless of mild to moderate CKD. Therefore, increasing the dose to

200\text{ mg}

daily and rechecking the level in

4

weeks is the most appropriate next step.

Step-by-Step Solution

Evaluate the current serum uric acid level against the therapeutic target.

The patient's uric acid is

7.8\text{ mg/dL}

, which is above the standard target of

< 6.0\text{ mg/dL}

Urate-lowering therapy must be titrated to a specific target to ensure the dissolution of monosodium urate crystals.

Assess the safety of dose titration in the context of the patient's comorbidities.

Allopurinol can be safely up-titrated in patients with chronic kidney disease.

While initiation doses should be lower in CKD to prevent hypersensitivity, capping the maximum dose prevents patients from reaching therapeutic targets.

Determine the appropriate duration for concurrent anti-inflammatory prophylaxis.

Colchicine must be continued for at least 3 to 6 months.

Rapid shifts in serum uric acid during titration can precipitate mobilization flares if prophylaxis is stopped prematurely.

Select the correct management step.

Increase the allopurinol dose to

200\text{ mg}

and schedule a re-check in

4

weeks.

This achieves the goal of gradual up-titration with appropriate monitoring intervals.

Key Concept

Allopurinol dose titration to a target serum uric acid of < 6.0 mg/dL

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic